EVOREL®, EVOREL® Sequi and EVOREL® Conti: Information about interruption of supply

The FSRH is aware of a shortage of HRT medications. We received the following statement from Janssen. According to Janssen, the manufacturer, there will be an interruption of supply to Evorel®, Evorel® Sequi and Evorel® Conti.

Full information from Janssen is below:

 

Summary

• There is an interruption of supply for Evorel®, Evorel® Sequi and Evorel® Conti that will result in shortages to patients. The product range will stockout at the end of October 2019.
• Janssen anticipate that pharmacies will be out of stock until mid-2020.
• Please discuss alternative treatment options with your patients.

Further information

Product availability has been impacted by increased demand in some countries including the UK, combined with issues in bulk supply, resulting in an accelerated depletion of current stock.

There is no impact on product quality of existing supplies of Evorel®, Evorel® Sequi or Evorel® Conti. At Janssen, patient well-being is our primary concern and we wish to apologise for this unfortunate situation.

Janssen will continue to take every available action to minimise the impact of this supply shortage and will provide status updates if the situation changes.

Call for reporting

Please continue to report suspected adverse reactions with any medicine or vaccine to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report adverse drug reactions online via the Yellow Card website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Alternatively, prepaid Yellow Cards for reporting are available by writing to FREEPOST YELLOW CARD (no other address details necessary), by emailing yellowcard@mhra.gov.uk, at the back of the British National Formulary (BNF), by telephoning the Commission on Human Medicines (CHM) free phone line: 0800 731 6789, or by downloading and printing a form from the Yellow Card section of the MHRA website.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset dates, treatment dates, product brand name and batch numbers.

Suspected adverse reactions should also be reported to Janssen-Cilag Limited. on tel.: 01494 567447, or by e-mail at dsafety@its.jnj.com

Company contact point

If you have further questions or require additional information, please contact: Janssen Medical Information Department: email: medinfo@its.jnj.com, telephone: 0800 731 8450 or 01494 567 444."